UFP Technologies, Inc. — Q3 2014 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2014. The interim financial statements are unaudited. UFP designs and manufactures products using foams, plastics, composites, and natural-fiber materials, serving medical, aerospace and defense, automotive, and packaging markets.
Financial performance
Amounts below are in millions, except per-share data and margins.
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Net sales | $35.406 | $34.700 | $104.040 | $104.229 |
| Gross profit / margin | $9.683 / 27.3% | $10.162 / 29.3% | $28.267 / 27.2% | $29.784 / 28.6% |
| Operating income | $3.098 | $4.484 | $9.080 | $12.073 |
| Net income | $2.066 | $2.887 | $5.988 | $7.899 |
| Diluted EPS | $0.29 | $0.41 | $0.84 | $1.11 |
| Operating cash flow | Not presented quarterly | $6.852 | $11.540 |
- Period-over-period: Q3 sales rose 2.0%, while operating income fell about 31% and net income about 28%. Nine-month sales slipped 0.2%; operating income declined 24.8% and net income about 24%.
- Margins and costs: Gross margin contracted by 2.0 percentage points in Q3 and 1.4 points year to date. Management cited higher employee health-care and fringe-benefit costs and manufacturing inefficiencies during the Michigan consolidation. SG&A rose 3.4% in Q3 and 2.6% year to date. Restructuring expense was $0.772 million in Q3 and $1.096 million year to date.
- Cash flow and investment: Nine-month operating cash flow was $6.852 million, down from $11.540 million. Capital expenditures were $10.940 million, primarily for manufacturing equipment and a Texas facility. Cash declined to $33.048 million from $37.303 million at year-end 2013.
- Liquidity and debt: The company had no borrowings on its $40 million unsecured revolver, which matures November 30, 2018, and reported compliance with its covenants. Term loans secured by molded-fiber machines totaled approximately $3.1 million; balance-sheet current and long-term debt was $3.112 million. Management said available resources, expected operating cash flow, and borrowing capacity should cover requirements for the next 12 months.
- Balance sheet: Total assets were $112.138 million versus $105.020 million at December 31, 2013; stockholders’ equity was $93.003 million versus $85.590 million. Inventories rose to $13.500 million from $11.048 million.
Business changes, outlook, and risks
- Q3 sales growth reflected approximately 60% higher aerospace and defense sales, largely due to a large one-time defense order, plus approximately 4% medical growth. Automotive sales declined 14% in Q3 and 6% year to date. Management said nine-month medical sales increased 3%.
- The company shifted from two reported segments to one operating and reportable segment, reflecting its consolidated operating approach, shared manufacturing processes, plant consolidations, and sales-force consolidation.
- The Michigan plant consolidation was substantially complete. Management expects approximately $750,000 in annual savings. The California consolidation was expected to be completed by December 31, 2014, with approximately $535,000 in one-time costs and approximately $550,000 in annual savings. Additional California-related restructuring charges were expected in Q4.
- No formal earnings or revenue guidance was provided. The company planned to continue adding manufacturing capacity and may pursue complementary acquisitions. Management’s liquidity outlook depends on future operating performance.
- Key stated risks include weak customer-market conditions, customer order cancellations or deferrals, customer concentration exposure, competition, difficulty winning new business, execution and integration of acquisitions, production-equipment implementation and utilization, and achieving planned savings from plant closures. The filing reported no material changes to previously disclosed risk factors or market risks.
- Other notable items: the large one-time defense order affected Q3 comparability; a retroactive 2012 R&D credit had reduced the comparable 2013 nine-month effective tax rate. The 2014 effective tax rate was approximately 35%.
Important facts for investors to verify
- Whether the defense order was nonrecurring and how aerospace and defense sales perform without it.
- Whether automotive demand stabilizes and medical-market growth continues.
- Whether Michigan and California consolidation savings are realized, and whether remaining costs stay near estimates.
- Whether gross margins recover as health-care costs and consolidation-related inefficiencies normalize.
- Whether capital spending, working-capital requirements, and operating cash flow support liquidity plans.
- Compliance with revolver covenants and the repayment schedule for the term loans.